Skip to content
ETopical – Lifestyle
Author:
Racura Oncology Limited
Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia
November 18, 2026
Racura Oncology Presents Bisantrene MYC Data at Frontiers in Cancer Science 2026 Conference
November 12, 2026
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
October 12, 2026
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
June 25, 2026